Abstract 

Objective: This study evaluates the effects of high-dose intravenous vitamin C therapy on cancer patients.

Context: Intravenous vitamin C administration can achieve plasma concentrations not attainable by oral ingestion. There is interest in using it as an adjuvant cancer therapy, but its efficacy is still under study.

Methods Used: A prospective cohort study was conducted on breast cancer patients receiving high-dose intravenous vitamin C along with standard chemotherapy. Quality of life, toxicities, and symptom burden were examined.

Researchers' Summary of Findings: Vitamin C therapy was associated with improvements in quality of life scores, lower chemotherapy-related side effects, and reduced cancer-related symptoms compared to control group.

Health Implications: High-dose intravenous vitamin C may enhance cancer patients' quality of life and tolerance of conventional treatment. More rigorous controlled trials are warranted to validate these findings.

DOI: 10.7150/jca.10688